
category:side-effects
Ozempic is not likely to directly enlarge the male appendage.
A critical look at the popular "ozempic penis" claims and look at the sources, along with possible reasons and related research.
Scouring sources for information on GLP1 Agonist drugs, so you don't have to.
category:side-effects
A critical look at the popular "ozempic penis" claims and look at the sources, along with possible reasons and related research.
company:eli-lilly
We take a look at some exciting upcoming presentations by Eli Lilly about it's old and new GLP1 receptor agonists.
research
Finally, a research clinical trial that directly explores the difference between Semaglutide and Tirzepatide for Obesity.
company:roche
We take a look at Roche (via Carmot)'s GLP1 pipeline development, and figure out how CT-388, CT-996, and CT-868 are trending.
category:news
New study suggests link between GLP1 Receptor Agonists (Ozempic, Mounjaro, etc) and kidney cancer.
malady:addiction
We trace research on GLP1s and addiction through the years and try to find studies that match the anecdotes.
drug:retatrutide
We take some time to check in on Retatrutide -- an update on how research and trials are progressing, and relevant news.
category:benefits
We look into the anti-inflammatory effects of GLP1s and their effects on issues like psoriasis and infertility.
politics
We take a look at the various movements in GLP1 policy by the Trump administration, so far.
drug:wegovy
Novo Nordisk is producing a pill form of Wegovy -- the only pill to be FDA approved (if/when it is) for weight loss.
drug:nimacimab
Nimacimab delivers excellent results and explores a new path: drugs meant to be taken *with* other GLP1s.
company:eli-lilly
Eli Lilly sues many compounding-related companies in an effort to clear the market of compounded GLP1.